Motorola Solutions Inc vs 10X Genomics Inc — how do they compare? Motorola Solutions Inc trades at $465.4 (market cap $77.26B), while 10X Genomics Inc trades at $57.95 (market cap $7.61B). The key difference: Motorola Solutions Inc is far larger — about 10.2× 10X Genomics Inc's market cap, and Motorola Solutions Inc pays a 1.04% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| MSI | TXG | |
|---|---|---|
Market Cap | $77.26B | $7.61B |
Sector | Technology | Health |
52-Week High | $490.30 | $58.57 |
52-Week Low | $363.83 | $11.34 |
Enterprise Value | $86.17B | $7.14B |
Dividend Yield | 1.04% | — |
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $461.98, down 1.19% today but has demonstrated strong momentum with three consecutive quarterly earnings beats and a 23.5% gain over three months. The company reported record Q2 2026 results with 13% revenue growth and raised full-year guidance, supported by a record $15.6 billion backlog. Technical indicators show a bullish trend with the stock near its pivot point of $463, while valuation metrics remain elevated with a P/E of 36.79.
The outlook remains positive given strong demand in public safety communications and software services, with analyst consensus pointing to 15% upside to the $533.80 price target. Key risks include execution challenges to meet elevated expectations and the premium valuation requiring sustained high growth. The combination of operational strength and bullish sentiment supports a constructive view for investors.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Trailing returns across standard periods
Latest headlines on both assets
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →